ASCO GU: With 2-year data, the jury’s still out on the kidney cancer race between Opdivo-Cabometyx and Keytruda-Inlyta February 9, 2021 Auto Bot News 0 ASCO GU: With 2-year data, the jury’s still out on the kidney cancer race between Opdivo-Cabometyx and Keytruda-Inlyta aliu Tue, 02/09/2021 – 10:59
